dc.contributor.author |
Melhem N. |
dc.contributor.author |
Yazbek S. |
dc.contributor.author |
Ramia S. |
dc.contributor.editor |
|
dc.date |
2012 |
dc.date.accessioned |
2017-10-18T13:38:22Z |
dc.date.available |
2017-10-18T13:38:22Z |
dc.date.issued |
2012 |
dc.identifier |
10.1007/s11901-012-0142-6 |
dc.identifier.isbn |
|
dc.identifier.issn |
15403416 |
dc.identifier.uri |
http://hdl.handle.net/10938/20719 |
dc.description.abstract |
Hepatitis D virus (HDV) is a defective RNA virus and its life cycle is dependent on hepatitis B virus (HBV). Worldwide, it is estimated that 15 to 20million individuals are HDV- infected representing approximately 5 percent of the 350 million cases of HBV chronically- infected individuals. The belief that HDVis under control is far from true. Studies from Europe have clearly shown that HDV reservoirs have been maintained via import from Southern or Eastern Europe, and from endemic areas such as countries of the Middle East and North Africa (MENA region). The current review highlights the underestimated disease burden caused by HDV in the MENA region. A series of recommendations are advanced which will contribute to the control of HBV-HDV in the MENA region and consequently in neighboring Europe. The lack of conclusive evidence on the best treatment strategy of HDV, necessitates continued research on HDV infection. © Springer Science+Business Media New York 2012. |
dc.format.extent |
|
dc.format.extent |
Pages: (272-278) |
dc.language |
English |
dc.relation.ispartof |
Publication Name: Current Hepatitis Reports; Publication Year: 2012; Volume: 11; no. 4; Pages: (272-278); |
dc.relation.ispartofseries |
|
dc.relation.uri |
|
dc.source |
Scopus |
dc.subject.other |
|
dc.title |
Hepatitis D in the middle east and north africa (MENA): Update and challenges ahead |
dc.type |
Article |
dc.contributor.affiliation |
Melhem, N., Faculty of Health Sciences, Medical Laboratory Sciences Program, American University of Beirut, Van Dyck Building, 11-0236 Riad El Solh, 1107-2020, Beirut, Lebanon |
dc.contributor.affiliation |
Yazbek, S., Faculty of Health Sciences, Medical Laboratory Sciences Program, American University of Beirut, Van Dyck Building, 11-0236 Riad El Solh, 1107-2020, Beirut, Lebanon |
dc.contributor.affiliation |
Ramia, S., Faculty of Health Sciences, Medical Laboratory Sciences Program, American University of Beirut, Van Dyck Building, 11-0236 Riad El Solh, 1107-2020, Beirut, Lebanon |
dc.contributor.authorAddress |
Ramia, S.; Faculty of Health Sciences, Medical Laboratory Sciences Program, American University of Beirut, Van Dyck Building, 11-0236 Riad El Solh, 1107-2020, Beirut, Lebanon; email: sramia@aub.edu.lb |
dc.contributor.authorCorporate |
University: American University of Beirut; Faculty: Faculty of Health Sciences; Department: Medical Laboratory Sciences Program; |
dc.contributor.authorDepartment |
Medical Laboratory Sciences Program |
dc.contributor.authorDivision |
|
dc.contributor.authorEmail |
|
dc.contributor.faculty |
Faculty of Health Sciences |
dc.contributor.authorInitials |
|
dc.contributor.authorOrcidID |
|
dc.contributor.authorReprintAddress |
|
dc.contributor.authorResearcherID |
|
dc.contributor.authorUniversity |
American University of Beirut |
dc.description.cited |
|
dc.description.citedCount |
|
dc.description.citedTotWOSCount |
|
dc.description.citedWOSCount |
|
dc.format.extentCount |
7 |
dc.identifier.articleNo |
|
dc.identifier.coden |
|
dc.identifier.pubmedID |
|
dc.identifier.scopusID |
84872269404 |
dc.identifier.url |
|
dc.publisher.address |
|
dc.relation.ispartofConference |
|
dc.relation.ispartofConferenceCode |
|
dc.relation.ispartofConferenceDate |
|
dc.relation.ispartofConferenceHosting |
|
dc.relation.ispartofConferenceLoc |
|
dc.relation.ispartofConferenceSponsor |
|
dc.relation.ispartofConferenceTitle |
|
dc.relation.ispartofFundingAgency |
|
dc.relation.ispartOfISOAbbr |
|
dc.relation.ispartOfIssue |
4 |
dc.relation.ispartOfPart |
|
dc.relation.ispartofPubTitle |
Current Hepatitis Reports |
dc.relation.ispartofPubTitleAbbr |
Curr. Hepatitis Rep. |
dc.relation.ispartOfSpecialIssue |
|
dc.relation.ispartOfSuppl |
|
dc.relation.ispartOfVolume |
11 |
dc.source.ID |
|
dc.type.publication |
Journal |
dc.subject.otherAuthKeyword |
Epidemiology |
dc.subject.otherAuthKeyword |
Genotypes |
dc.subject.otherAuthKeyword |
HBV |
dc.subject.otherAuthKeyword |
HDV |
dc.subject.otherAuthKeyword |
MENA |
dc.subject.otherChemCAS |
adefovir, 106941-25-7 |
dc.subject.otherChemCAS |
immunoglobulin G, 97794-27-9 |
dc.subject.otherChemCAS |
immunoglobulin M, 9007-85-6 |
dc.subject.otherChemCAS |
lamivudine, 134678-17-4, 134680-32-3 |
dc.subject.otherIndex |
adefovir |
dc.subject.otherIndex |
alpha interferon |
dc.subject.otherIndex |
hepatitis B surface antigen |
dc.subject.otherIndex |
hepatitis B vaccine |
dc.subject.otherIndex |
immunoglobulin G |
dc.subject.otherIndex |
immunoglobulin M |
dc.subject.otherIndex |
interferon |
dc.subject.otherIndex |
lamivudine |
dc.subject.otherIndex |
nucleoside |
dc.subject.otherIndex |
nucleotide |
dc.subject.otherIndex |
peginterferon alpha |
dc.subject.otherIndex |
RNA directed RNA polymerase inhibitor |
dc.subject.otherIndex |
virus RNA |
dc.subject.otherIndex |
article |
dc.subject.otherIndex |
delta agent hepatitis |
dc.subject.otherIndex |
disease carrier |
dc.subject.otherIndex |
enzyme linked immunosorbent assay |
dc.subject.otherIndex |
Hepatitis B virus |
dc.subject.otherIndex |
Hepatitis delta virus |
dc.subject.otherIndex |
human |
dc.subject.otherIndex |
incidence |
dc.subject.otherIndex |
infection control |
dc.subject.otherIndex |
Middle East |
dc.subject.otherIndex |
nonhuman |
dc.subject.otherIndex |
North Africa |
dc.subject.otherIndex |
prevalence |
dc.subject.otherIndex |
RNA virus |
dc.subject.otherKeywordPlus |
|
dc.subject.otherWOS |
|